Brian W. Loggie, MD

Surgical Oncologist

Conditions Treated

Ovarian Cancer Pericardial Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

Bio & Insurance Information

A native of Montreal, Canada, Dr. Brian Loggie completed the courses of Loyola College and graduated from the McGill University Medical School. He completed his residency at the Montreal General Hospital and moved to Chicago afterwards to complete a fellowship at the University of Illinois. Currently the chief of the surgical oncology division at the Creighton University Medical Center, Dr. Brian Loggie’s specialty and main focus is mesothelioma. As a surgical oncologist, Dr. Loggie has been well respected in the field for the last several decades, and uses highly effective techniques for treating mesothelioma and any damage this causes through minimally invasive surgical interventions. He is board certified in surgical oncology.


Education & Training

Loyola College, Montreal, Canada - 1974

Education

McGill University, Montreal, Canada - 1979

Medical School

Montreal General Hospital, Montreal, Canada (1980-1986)

Residency

University of Illinois at Chicago, Chicago, Illinois (1986-1988)

Fellowship

Board Certifications

American Board of Surgery

Hospitals & Clinics

Boys Town National Research Hospital

Languages: English/Spanish

(402) 498-6511

555 North 30th Street

Omaha, Nebraska 68131

Read More

Creighton University Medical Center

Languages: English/Spanish

(402) 449-4000

601 North 30th Street

Omaha, Nebraska 68131

Read More

Publications

Dr. Brian W. Loggie has contributed to 3 publications.

Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma.

Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW.

See more >>

Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.

Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, Nath SK, Loggie BW.

See more >>

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.

Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW.

See more >>

Memberships

Society of Surgical Oncology

American College of Surgeons

American Medical Association

American Society of Clinical Oncology

Association for Academic Surgery

June 25, 2016

by Michele K.

Wait Time

Staff

Helpfulness

Knowledge

“Twenty years ago when I was 49 I found out that I had a rare form of cancer and only 6 months to live. I was referred to Dr. Loggie and became his patient in his NIH study using hot chemo. I could not have had a better doctor to guide me through this difficult road. Dr. Loggie never gave up on me, even when I felt like quitting.”